About
Dr. Delalle's works bridges basic and clinical science to advance the understanding of the pathogenesis of neurodegenerative diseases. Her present focus, supported by the by the National Institute of Aging, is on novel, early, and reliable
... biomarkers of Alzheimer’s Disease (AD). Recent studies, directed by Dr. Delalle and her co-senior authors at the University of Goettingen, Germany, and Indiana University, demonstrated that evaluating microRNAs in blood can be used not only to diagnose mild cognitive impairment (MCI) but also, critically, to predict the conversion from MCI to AD. Moreover, the team uncovered microRNA candidate molecular biomarkers that associate with current Amyloid, Tau, and Neurodegeneration AD biomarkers. These novel findings are important because, unlike current AD biomarkers, microRNAs may serve as blood molecular biomarkers years before AD-associated clinical symptoms begin, enabling successful AD prevention and/or early intervention to stop AD.
-
Specialties
Neuropathology, Anatomic Pathology, Neuromuscular Disorders
-
Contact
617.638.4500 -
Primary Location
-
Administrative Title
Professor of Pathology & Laboratory Medicine and Anatomic Pathology, Boston University Chobanian & Avedisian School of Medicine
-
Residency
Pathology—Anatomic and Clinical, Massachusetts General Hospital, 1997–1999
-
Fellowship
Neuropathology, Massachusetts General Hospital, 1999–2001
-
Education
University of Zagreb Faculty of Medicine, 1988
-
Board Certifications
Anatomic Pathology and Neuropathology, American Board of Pathology
-
Research Interests
Neurodegenerative Diseases
